Feedback
HIV-1 Integrase Inhibitor Resistance by Sequencing
2004457
Ordering Recommendation
 
Mnemonic
HIV1INT
Methodology
Reverse Transcription Polymerase Chain Reaction/Sequencing
Performed
Tue, Fri
Reported
7-10 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
 
Specimen Required
Patient Preparation
  
Collect
Lavender (EDTA), pink (K2EDTA), or plasma preparation tube.  
Specimen Preparation
Separate plasma from cells within 6 hours. Transfer 4 mL plasma to an ARUP Standard Transport Tube. (Min: 1.5 mL)  
Storage/Transport Temperature
Frozen.  
Unacceptable Conditions
Serum. Heparinized specimens.  
Remarks
Please submit most recent viral load and test date, if available.  
Stability
On cells: Ambient: 6 hours; After separation from cells: Ambient: 24 hours; Refrigerated: 5 days; Frozen: 4 months  
Reference Interval
By report  
Interpretive Data
The entire integrase-encoding region is sequenced. Mutations associated with resistance to integrase inhibitors are reported. Mutations in viral sub-populations below 20 percent of total may not be detected.

See Compliance Statement D: www.aruplab.com/CS
Statement D: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
 
Note
This test may be unsuccessful if the plasma HIV-1 RNA viral load is less than 500 HIV-1 RNA copies per mL of plasma.
CPT Code(s)
87906 
Components
Component Test Code*Component Chart NameLOINC
2004458HIV-1 Integrase Inhib. Resistance, Seq72560-6
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • HIV Drug Resistance
  • HIV Integrase Genotype
  • HIV Integrase Inhibitor Resistance
  • HIV Treatment Susceptibility Testing
  • HIV1 Integrase Resistance
  • HIV1 Integrase Sequencing
  • HIV1 Sequencing
  • Raltegravir (Isentress(TM)) Resistance